Takeda Pharmaceutical CO LTD
Forward trial catalysts linked to TAK
CSA tracks 2 forward catalysts for Takeda Pharmaceutical CO LTD across 1 asset, spanning Phase 3. The nearest is a readout expected May 18, 2027 (day precision). Confidence across its tracked catalysts breaks down as 2 medium. Tracked indications include Plaque Psoriasis, Psoriatic Arthritis, Palmoplantar Psoriasis.
TAK in the full snapshot
The free sample on this page is a slice. In the current full CSA snapshot, Takeda Pharmaceutical CO LTD has:
Forward catalysts by year
Every catalyst in the snapshot comes with its date, date confidence and source link.
6 trials behind these assets
| Asset | Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|---|
| zasocitinib | NCT06671483 catalyst | Phase 3 | Recruiting | 2027-05-18 | Experimental | Takeda | Psoriatic Arthritis |
| zasocitinib | NCT06671496 | Phase 3 | Recruiting | 2027-05-18 | Experimental | Takeda | Psoriatic Arthritis |
| zasocitinib | NCT07752108 catalyst | Phase 3 | Not yet recruiting | 2027-05-30 | Experimental | Takeda | Palmoplantar Psoriasis |
| zasocitinib | NCT06550076 | Phase 3 | Active, not recruiting | 2029-08-05 | Experimental | Takeda | Plaque Psoriasis |
| zasocitinib | NCT07286058 | Phase 3 | Recruiting | 2029-12-18 | Experimental | Takeda | Psoriatic Arthritis |
| zasocitinib | NCT07250802 | Phase 3 | Recruiting | 2033-01-24 | Experimental | Takeda | Plaque Psoriasis |
Every trial the CSA sample links to TAK's tracked assets.
Conditions studied
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This sponsor's catalysts are a slice of the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 →